Text Size
Trial record 7 of 35 for:    Open Studies | "Potassium"
Previous Study | Return to List | Next Study

Efficacy and Tolerance of Potassium Hydroxide (10% and 15%) in Molluscum Contagiosum (EKOH-MOL 2008)

The recruitment status of this study is unknown because the information has not been verified recently.
Verified May 2011 by Jordi Gol i Gurina Foundation.
Recruitment status was  Recruiting
Sponsor:
Information provided by:
Jordi Gol i Gurina Foundation
ClinicalTrials.gov Identifier:
NCT01348386
First received: May 4, 2011
Last updated: May 19, 2011
Last verified: May 2011
History of Changes
  Purpose

BACKGROUND:

Molluscum contagiosum is a non-serious children viral infection. Because of its natural history, being highly contagious and the aesthetic and psychotherapeutic effects of its treatment, the investigators intend to test the use of different concentrations of potassium hydroxide solution in the primary care setting.

METHODS:

A double blind, randomized clinical trial, in three groups of topic treatment is designed. The intended treatment consists on a daily application of potassium hydroxide in aqueous solution at 10% and 15% concentration, versus a placebo administered to the control group. 4 follow-up visits (15, 30, 45 and 60 days) are planned to evaluate treatment effectiveness and tolerance.

The main target of the trial is to determine the healing rate, defined as lesion disappearance in the affected zones after the topic application of the treatment. Secondary targets are the main characteristics and evolution of the affected zone (surface, number of lesions, size and density) description, tolerance evaluation (hyperpigmentation, itching, burning, pain), recurrence rate estimation and natural evolution of lesions in the control group.


Condition Intervention Phase
Molluscum Contagiosum
 Drug: Hydroxide Potassium
Drug: Placebo
 Phase 2
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Official Title: Efficacy and Tolerance of the Topical Application of Potassium Hydroxide (10% and 15%) in the Treatment of Molluscum Contagiosum

Resource links provided by NLM:

MedlinePlus related topics: Potassium
U.S. FDA Resources

Further study details as provided by Jordi Gol i Gurina Foundation:

Primary Outcome Measures:
  • Efficacy (diseappearance of lesions) [ Time Frame: 60 days ] [ Designated as safety issue: No ]

Estimated Enrollment: 60
Study Start Date: March 2010
Estimated Study Completion Date: March 2012
Estimated Primary Completion Date: March 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: KOH 10%
Treatment consists of the application of topical 10% KOH in an aqueous solution.
 Drug: Hydroxide Potassium
Treatment will consist of the application of topical 10% or 15% KOH in an aqueous solution for the two treatment groups, compared to a placebo-treated control group. Topical Application.
Experimental: KOH 15%
Treatment consists of the application of topical 15% KOH in an aqueous solution
 Drug: Hydroxide Potassium
Treatment will consist of the application of topical 10% or 15% KOH in an aqueous solution for the two treatment groups, compared to a placebo-treated control group. Topical Application.
Placebo Comparator: PLACEBO
100 milliliters of saline solution
 Drug: Placebo

  Eligibility

Ages Eligible for Study:   2 Years to 6 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Who are diagnosed with a molluscum contagiosum (MC) infection (clinical diagnosis).
  • Who are between the ages of two and six.
  • Whose parents or guardians have provided written informed consent for participation.

Exclusion Criteria:

  • Immunocompromised patient (congenital or acquired).
  • Patient has received other topical treatment within the last month.
  • Patient has lesions on face, neck or genital area.
  • Patient who, in the view of the attending physician, will not comply with treatment and/or scheduled visits.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01348386

Contacts
Contact: Josep Ramon Sr. Marsal +0034 973 72 82 55 ext 302 jmarsal@gencat.cat

Locations
Spain
CAP Rambla Ferran Recruiting
Lleida, Catalunya, Spain, 25001
Contact: Josep Ramon Sr Marsal     +0034 973 72 82 55 ext 302     jmarsal.lleida.ics@gencat.cat    
Principal Investigator: Olga Sra. Diez            
Sponsors and Collaborators
Jordi Gol i Gurina Foundation
  More Information

No publications provided by Jordi Gol i Gurina Foundation

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Responsible Party: Conxita Teixidor, Institut Catala de la Salut (ICS)
ClinicalTrials.gov Identifier: NCT01348386     History of Changes
Other Study ID Numbers: EC08/00011
Study First Received: May 4, 2011
Last Updated: May 19, 2011
Health Authority: Spain: Agencia Española de Medicamentos y Productos Sanitarios

Keywords provided by Jordi Gol i Gurina Foundation:
Potassium hydroxide.
Molluscum Contagiosum

Additional relevant MeSH terms:
Molluscum Contagiosum
Poxviridae Infections
DNA Virus Infections
Virus Diseases
 Skin Diseases, Viral
Skin Diseases, Infectious
Skin Diseases

ClinicalTrials.gov processed this record on May 22, 2013